Skip to Content
Merck

S0650000

Simvastatin

European Pharmacopoeia (EP) Reference Standard

Slide 1 of 1
Sign In to View Organizational & Contract Pricing.

Select a Size

200 MG

CZK 3,880.00

CZK 3,880.00

Please contact Customer Service for Availability
Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):
C25H38O5
CAS Number:
79902-63-9
Molecular Weight:
418.57
NACRES:
NA.24
PubChem Substance ID:
329824434
UNSPSC Code:
41116107
MDL number:
MFCD00072007

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Simvastatin, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1

SMILES string

[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]3C[C@@H](O)CC(=O)O3)OC(=O)C(C)(C)CC

InChI key

RYMZZMVNJRMUDD-HGQWONQESA-N

grade

pharmaceutical primary standard

API family

simvastatin

manufacturer/tradename

EDQM

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

mp

127-132 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

Gene Information

human ... HMGCR(3156)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
161270038956S6196
Simvastatin European Pharmacopoeia (EP) Reference Standard

S0650000

Simvastatin

Simvastatin United States Pharmacopeia (USP) Reference Standard

USP

1612700

Simvastatin

Simvastatin analytical standard

Supelco

38956

Simvastatin

Simvastatin ≥97% (HPLC), solid

Sigma-Aldrich

S6196

Simvastatin

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

technique(s)

-

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

forensics and toxicology
pharmaceutical (small molecule)
veterinary

application(s)

-

format

neat

format

neat

format

neat

format

-

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

analytical standard

grade

-

manufacturer/tradename

EDQM

manufacturer/tradename

USP

manufacturer/tradename

-

manufacturer/tradename

-

API family

simvastatin

API family

simvastatin

API family

-

API family

-

Application

Simvastatin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Simvastatin is a specific inhibitor of HMG-CoA reductase and cholesterol lowering drug.
Simvastatin is a specific inhibitor of HMG-CoA reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early step in cholesterol biosynthesis. It is used in the treatment of hypercholesterolemia, as it reduces levels of low-density lipoproteins and triglycerides, and raises high-density lipoprotein levels. Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding β-hydroxyacid, and can be activated prior to use with NaOH in EtOH treatment. It is a synthetic analog of lovastatin (Cat. No. M2147).

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

pictograms

Health hazard
GHS08

signalword

Warning

hcodes

H361d

Hazard Classifications

Repr. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Heiner K Berthold et al.
PloS one, 8(3), e60095-e60095 (2013-04-02)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted inhibitor of the low-density lipoprotein (LDL) receptor and an important regulator of LDL metabolism. Elevated PCSK9 levels have been associated with cardiovascular risk. The purpose of this study was to investigate
Thijs van der Vaart et al.
The Lancet. Neurology, 12(11), 1076-1083 (2013-10-05)
Neurofibromatosis type 1 is a common genetic disorder characterised by neurocutaneous manifestations and cognitive and behavioural problems. Statins were shown to reduce analogous learning deficits in a mouse model of the disease, but a short-term trial in humans was inconclusive.
Kirill Tarasov et al.
The Journal of clinical endocrinology and metabolism, 99(1), E45-E52 (2013-11-19)
Coronary artery disease (CAD) is among the leading causes of mortality and morbidity worldwide. Traditional risk markers explain only a proportion of total cardiovascular risk. Thus, development and improvement of early diagnostic strategies and targeted initiation of preventive measures would
Veluchamy A Barathi et al.
Investigative ophthalmology & visual science, 55(1), 460-468 (2014-01-09)
To determine the effect of a statin (simvastatin) on the ultrastructure and function of the RPE, Bruch's membrane (BM), and photoreceptor interface in a high-fat atherogenic mouse model of thickened BM. Wild-type C57BL/6 mice (6-weeks old) were divided into three
Colin R Dormuth et al.
BMJ (Clinical research ed.), 346, f880-f880 (2013-03-21)
To quantify an association between acute kidney injury and use of high potency statins versus low potency statins. Retrospective observational analysis of administrative databases, using nine population based cohort studies and meta-analysis. We performed as treated analyses in each database
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service